Partnership drives advances in cell therapy manufacturing

Sartorius Stedim Biotech and Nanotein Technologies have formed a strategic partnership to advance immune cell activation and expansion for cell therapy manufacturing. As part of the collaboration, Sartorius will take a minority stake in Nanotein and secure exclusive global distribution of Nanotein’s NanoSpark® activation products, including STEM-T Soluble T Cell Activator and GROW-NK Soluble Activator.

The reagents are designed to enhance T cell and natural killer (NK) cell expansion, addressing critical challenges in cell therapy production such as inconsistent yields and reliance on feeder cells. The partnership also includes joint development of new solutions for the rapidly growing cell and gene therapy markets.

“Together, we are providing cell therapy manufacturers with tools to simplify workflows and accelerate innovation from process development to the clinic,” said René Fáber, CEO of Sartorius Stedim Biotech.
Nanotein’s NanoSpark® technology uses a fully soluble protein scaffold with functional antibodies to stimulate immune cells effectively, delivering higher yields of therapeutically functional cells.

More information online